Navigation Links
Karmanos Cancer Institute Research Supports Role of Inflammation to Determine Lung Cancer Risk, Particularly in African-American Women

SAN DIEGO, April 14 /PRNewswire-USNewswire/ -- Researchers at the Barbara Ann Karmanos Cancer Institute in Detroit today presented findings that support the role of inflammation in determining lung cancer risk, particularly among African-American women.

(Logo: )

The abstract titled, Cytokine SNPs Differentially Predict Risk of Non Small Cell Lung Cancer in African American and Caucasian Women, was given at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA.

The study's goal was to determine whether variation in genes in the inflammatory pathway contribute to the risk of non-small cell lung cancer, and whether there are differences by race, according to Karmanos Principal Investigator Alison L. Van Dyke, MD/PhD Candidate, Class of 2011. Genetic variation was evaluated by looking at single nucleotide polymorphisms (SNPs) in cytokine genes.

Population-based cases included 95 African-American and 365 Caucasian women, aged 18-74. Each had been diagnosed with primary non-small cell lung cancer in metropolitan Detroit during a four year period. 483 controls were frequency matched to cases based on age and race. Analyses were performed separately for African-American and Caucasian women, and adjustments were made for factors such as body mass index, age and education, smoking history, family history of lung cancer and history of chronic lung disease.

"Our findings show that there is a 2.2 fold increased risk for African-American women to develop lung cancer if carrying a particular SNP in IL10 as compared to African-American women who do not," said Karmanos Associate Center Director of Population Sciences Ann Schwartz, Ph. D., M.P.H. She added that there was a decreased risk for lung cancer among Caucasian women with this polymorphism. A nearby SNP on the IL10 gene was also associated with an increased risk of lung cancer among African-American women but a decreased risk among Caucasian women.

"These results suggest racial differences in the relationship between cytokine SNPs and risk of lung cancer, but larger studies need to be conducted in diverse populations to confirm these findings," said Dr. Schwartz.

According to Van Dyke, this type of information might be used to better predict who to screen for lung cancer for earlier disease detection and may lead to more targeted treatments.

"It is important that we identify disease markers for lung cancer," she said. "If diagnosed at a localized stage, the overall five-year survival rate is approximately 50 percent, yet when lung cancer is diagnosed a distant stage of disease, the five-year survival rate is only two percent."

Dr. Schwartz added, "Lung cancer remains the number one cancer killer among men and women in the United States. "If we can better predict who is at risk and then diagnose disease earlier, rates of survival will improve dramatically."

The study was funded by the National Cancer Institute. Other Karmanos Cancer Institute and Wayne State University investigators include Michele L. Cote, Ph. D., assistant professor of Internal Medicine; Angie S. Wenzlaff, M.P.H., research assistant, Epidemiology; Susan Land, Ph. D., principal investigator, Genomics Core; and Geoffry Prysak, M.P.H. and Gina B. Claeys, M.P.H., project managers.

About the Barbara Ann Karmanos Cancer Institute

Located in mid-town Detroit, MI, the Barbara Ann Karmanos Cancer Institute is one of 39 National Cancer Institute-designated comprehensive cancer centers in the United States. Caring for more than 6,000 new patients annually on a budget of $216 million, conducting more than 700 cancer-specific scientific investigation programs and clinical trials, the Karmanos Cancer Institute is among the nation's best cancer centers. Through the commitment of 1,000 staff, including nearly 300 faculty members, and supported by thousands of volunteer and financial donors, the Institute strives to prevent, detect and eradicate all forms of cancer. John C. Ruckdeschel, M.D., is the Institute's president and chief executive officer. For more information call 1-800-KARMANOS or go to

American Association for Cancer Research

The mission of the American Association for Cancer Research is to prevent and cure cancer. Founded in 1907, AACR is the world's oldest and largest professional organization dedicated to advancing cancer research. The AACR Annual Meeting attracts more than 17,000 participants who share the latest discoveries and developments in the field.

SOURCE Karmanos Cancer Institute
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Karmanos Researchers Find Non-Toxic Agents Added to Conventional Chemotherapy Decrease Survival of Colon Cancer Cells
2. Karmanos Researchers Study the Impact of Galectin-3 on Breast Cancer Disparity in Caucasian and Asian Women
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
6. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. Novel Technology Breaks Through Cancer Pain
10. CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug
11. Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms
Post Your Comments:
(Date:11/26/2015)... DUBLIN , November 26, 2015 ... has announced the addition of the  ... in the European Cell Surface Marker ... Emerging Opportunities"  report to their offering.  ... announced the addition of the  "2016 ...
(Date:11/25/2015)...  Amgen (NASDAQ: AMGN ) today announced the ... the United States (U.S.) Food and ... to Humira ® (adalimumab). Amgen believes this submission ... FDA and represents Amgen,s first BLA submission using the ... M.D., executive vice president of Research and Development at ...
(Date:11/25/2015)... 25, 2015 AAIPharma Services Corp./Cambridge Major ... at least $15.8  Million to expand its laboratories ... . The expansion will provide additional office ... growing demands of the pharmaceutical and biotechnology markets. ... will provide up to 40,000 square feet of ...
Breaking Medicine Technology:
(Date:11/27/2015)... MINNEAPOLIS, Minn. (PRWEB) , ... November 27, 2015 ... ... you start failing. Secura Consultants has prided itself for not only fulfilling the ... best income protection solutions at an affordable price and providing top-tier customer service. ...
(Date:11/27/2015)... CA (PRWEB) , ... November 27, 2015 , ... ... on Accreditation of Allied Health Education Programs (CAAHEP) awarded accreditation to its Diagnostic Medical ... of CAAHEP accredited colleges, as only one of twelve colleges and universities in the ...
(Date:11/27/2015)... ... ... Dr. Thomas Dunlap and Dr. Patrick Coleman , cardiologist ... Medicine at St., Joseph Health System’s Santa Rosa Memorial Hospital , co-hosted the ... ways and require time-critical intervention to avoid large area heart damage and progressive infections ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... contact center software Q-Suite, announces the incorporation of Asterisk 11 LTS (Long Term ... fully supported Asterisk 11 LTS brings Q-Suite 5.10 up-to-date with a version of ...
(Date:11/26/2015)... ... , ... Inevitably when people think Thanksgiving, they also think Holiday sales and ... Friday and Cyber Monday massage chair sales to receive the best pricing ... to find the best massage chair deals, they can see all of the coupons ...
Breaking Medicine News(10 mins):